Esperion Therapeutics goes private as $1.1B ArchiMED acquisition closes

summarizeSummary

Esperion Therapeutics completed its acquisition by ArchiMED for $3.16/share in cash plus CVRs worth up to $100M. The stock will be delisted; former shareholders now hold only CVRs tied to drug sales milestones.

check_boxKey Events · M&A and Partnerships · ESPR

• Merger Closed

  Essence Parent Inc. (ArchiMED) has acquired Esperion Therapeutics for $3.16 per share in cash plus one CVR per share, with total cash consideration of approximately $1.1 billion.

• CVR Agreement

  Each CVR entitles holders to a pro rata share of up to $100 million in aggregate contingent payments if certain sales milestones for NEXLETOL/NEXLIZET and ENBUMYST are achieved by 2027 and 2030, respectively.

• Delisting and Going Private

  Esperion's common stock will be delisted from Nasdaq; the company will file Form 15 to suspend SEC reporting obligations, ending its public company status.

• Debt Refinancing

  A new loan agreement with BioPharma Credit PLC and others was entered into, and the prior credit agreement was repaid and terminated.

auto_awesomeAnalysis · ESPR · Life Sciences

The acquisition of Esperion Therapeutics by Essence Parent Inc., an ArchiMED affiliate, has closed in an all-cash transaction valued at approximately $1.1 billion. Shareholders receive $3.16 per share plus one contingent value right (CVR) per share, which together could deliver up to an additional $100 million in aggregate if certain sales milestones for NEXLETOL/NEXLIZET and ENBUMYST are met. Following shareholder approval on July 8, the deal closed today, triggering the delisting of Esperion's common stock from Nasdaq and the end of its public company status. Funding came from equity contributions and a new loan agreement that also refinanced existing debt. This is a thesis-altering event: the public float is eliminated, and former shareholders now hold only contractual rights to future milestone payments.